China Pharmaceutical University (CPU), situated in the historical and cultural city of Nanjing, is one of the “211 Project” and “985 Innovative Platforms for Key Disciplines Project” key universities affiliated to the Ministry of Education of China. The University was founded in 1936 as China's first independent four-year National College of Pharmacy and the first public institution for higher pharmaceutical education in China. CPU is a multi-disciplinary research-oriented university with a specialization in pharmacy. Known as the “cradle of China’s biomedicine professionals”, the university has established itself as a leading institution in the development of pharmacy discipline clusters, particularly in the areas of pharmacy and traditional Chinese pharmacy. In 2017, CPU is included in the national “Double First-Class University Plan”.
CPU is composed of two campuses, namely the Xuanwumen Campus and the Jiangning Campus, which cover a total area of about 2,100 mu(about 146.6 hectares) to host its 19,457 full-time students.
Faculty and Staff
CPU possesses a strong team of faculty with abundant renowned experts in pharmacy. Currently, CPU has 1,865 faculty and staff members, and among them, 228 with professional titles, and 523 with associate professional titles, including one academician of the Chinese Academy of Engineering, one academician of the German National Academy of Sciences, 14 national high-level talents, 38 national high-level youth talents, one “National Huang Danian Model Faculty Team”, two National Excellent Teachers, and numerous national and provincial talents. There are currently 21 national and provincial innovation teams at CPU, including one innovative research team supported by the National Natural Science Foundation of China and two supported by the Ministry of Education.
The university proactively develops a scheme for talent growth that encompasses “Xing Yao Prestigious Scientists, Xing Yao Outstanding Scientist, Xing Yao Academic Leaders, Xing Yao Leading Scholars, and Xing Yao Innovative Scholars”.
Academic Disciplines and Majors
The university now has 3 authorized doctoral programs (first-level) in Pharmacy, Traditional Chinese Pharmacy, and Biology, one professional doctoral program in Biology and Medicine, 8 master’s programs (first-level) in Pharmacy, Traditional Chinese Pharmacy, Biology, Chemistry, Biomedical Engineering, Basic Medicine, Public Management, and Public Health and Preventive Medicine, and five professional master’s programs in Pharmacy, Traditional Chinese Pharmacy, Biology and Medicine, Applied Statistics, and Public Management. The university has 2 post-doctoral research stations in Pharmacy and Traditional Chinese Pharmacy that accept postdoctoral fellows in 3 first-level disciplines and 23 Second-level disciplines. The Pharmacy discipline is designated “first-level State Key Discipline” with six “second-level State Key Disciplines” including Medicinal Chemistry, Pharmaceutics, Pharmacognosy, Pharmaceutical Analysis, Microbiology and Biochemical Pharmacy, and Pharmacology. The Traditional Chinese Pharmacy discipline has been listed under National “Double-First Class” developing project.
The university is committed to building a world-class modern pharmaceutical discipline system that is developed around the concept of “Pharmacy + X” and is characterized by “New Pharmaceutical Sciences”. The Traditional Chinese Pharmacy discipline has been listed under the National “Double-First Class” developing project. The university's Pharmacology and Toxicology, Chemistry, Clinical Medicine, Biology and Biochemistry, Materials Science, Agricultural Science, and Neuroscience and Behavior programs are included in the top 1% of the Global ESI ranking. Among them, the Pharmacology and Toxicology program ranks No. 1 in Asia and No. 19 globally, with a percentile score of 1‰. In the 2023 US News college ranking, the Pharmacology and Toxicology discipline ranked No. 7 in the world.
The university offers 31 undergraduate programs across its 16 schools and departments. Among them, nine programs have been designated National First-class construction programs, which include Pharmacy, Traditional Chinese Pharmacy, Biopharmaceuticals, Pharmaceutical Engineering, Clinical Pharmacy, Pharmaceutical Formulation, Medicinal Chemistry, Pharmaceutical Administration, and Traditional Chinese Pharmacy Resource and Development.
CPU values both basic research and the R&D of new drugs. The university has established the State Key Laboratory "Multi-target Natural Drugs" ,as well as 35 national and provincial level labs, technology platforms, and engineering and technology centers that facilitate preclinical studies on new drug development in chemical drugs, traditional Chinese Pharmacy, and biological medicines, and provide end-to-end services for the R&D of new drugs. CPU has received four National Awards for Science and Technology Progress in recent years and one National Award for Technological Inventions. Researchers at CPU have published nearly 350 high-quality papers in top scientific journals as first or corresponding authors. CPU ranks first among all universities in the number of National Science and Technology Major Projects of the Ministry of Science and Technology of China related to innovations in drug manufacturing. CPU has taken the lead in seven national key R&D projects, including four projects with funding exceeding 20 million RMB. The National Natural Science Foundation of China has approved and provided support for 934 projects at CPU, with a total funding of 505 million RMB, out of which there are 35 projects categorized as major, key, or outstanding talent projects.
In response to national strategic needs, CPU has developed over 115 platforms that promote the transformation of scientific and technological achievements, creating a collaborative system for technology transfer centers, intellectual property centers, and local research institutes. Since the 12th Five-Year Plan, the university has provided more than 5,500 key technical services in drug R&D to over 2,200 enterprises and institutions with total amounts of over 4.3 billion RMB, including 585 technology service agreements with individual contract funding exceeding one million RMB. CPU possesses two New Drug Certificates and 20 new drug clinical approval. It holds 1,483 patents, 161 of which have been transformed into commercial products with total amount of 1.98 billion RMB, including ten patent transformation agreements with individual contract funding exceeding 100 million RMB and 32 exceeding 10 million RMB. CPU has been awarded honors such as the China Industry-University-Research Cooperative Promotion Award and the Golden Bridge Award. In total, it has developed over 1,000 new drugs and generics, including but not limited to, Guan-fu base A hydrochloride, Epristeride, Edaravone, Ginkgolide Injection, Irinotecan, Vinorelbine, and Diclofenac Sodium Gel, created direct economic benefits of over 200 billion RMB. It is also a testament to the CPU’s leading role in boosting the development of the national pharmaceutical industry.